This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Progenics (PGNX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Progenics (PGNX) delivered earnings and revenue surprises of 18.52% and -20.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Progenics (PGNX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Progenics (PGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Progenics (PGNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Progenics (PGNX) delivered earnings and revenue surprises of -9.52% and 55.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Progenics (PGNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Progenics (PGNX) delivered earnings and revenue surprises of 8.33% and 15.39%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Progenics (PGNX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Progenics (PGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Progenics (PGNX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Progenics (PGNX) delivered earnings and revenue surprises of -112.50% and -70.54%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Progenics (PGNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Progenics (PGNX) delivered earnings and revenue surprises of 50.00% and 28.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Progenics (PGNX) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Progenics (PGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Generic-Drugs Stock Outlook: No Respite from Pricing Issues
by Zacks Equity Research
Generic drugmakers, in general, are having a rather poor year, primarily due to ongoing pricing pressure and rising competition.
Progenics Pharma's Stock Down on Dismal Phase III Study Data
by Zacks Equity Research
Progenics Pharmaceuticals' (PGNX) shares down on disappointing results from phase III study evaluating imaging agent, 1404, for prostate cancer detection.
4 Drug and Biotech Stocks Awaiting FDA Decisions in July
by Kinjel Shah
In the first six months of the year, the FDA grants approval to 17 new treatments.
Zacks.com featured highlights include: VASCO Data, Progenics, Denny's, Columbus McKinnon and Equity Commonwealth
by Zacks Equity Research
Zacks.com featured highlights include: VASCO Data, Progenics, Denny's, Columbus McKinnon and Equity Commonwealth
5 Stocks in Focus on New Analyst Coverage
by Zacks Equity Research
More analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
Zacks.com featured highlights include: Camtek, Progenics Pharmaceuticals, Denny's and Dropbox
by Zacks Equity Research
Zacks.com featured highlights include: Camtek, Progenics Pharmaceuticals, Denny's and Dropbox
New Analyst Coverage Puts Spotlight on These 4 Stocks
by Zacks Equity Research
More analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
PetMed (PETS) Beats Earnings, Revenue Estimates in Q4
by Zacks Equity Research
PetMed Express, Inc. (PETS) announced earnings per share of 37 cents for the fourth quarter of fiscal 2017, up 37% from the year-ago quarter's 27 cents.
Henry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View
by Zacks Equity Research
Henry Schein, Inc. (HSIC) reported adjusted earnings per share (EPS) of $1.76 in the first quarter of 2017, up 24.8% year over year.
Haemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View
by Zacks Equity Research
Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2017, up 5.4% year over year.
Phibro (PAHC) Posts In Line Earnings in Q3, Revises View
by Zacks Equity Research
Phibro Animal Health Corporation (PAHC) reported adjusted earnings per share (EPS) of 37 cents in the third quarter of fiscal 2017, down 7.5% year over year.
Align Technology Invisalign Sales Strong, Currency Woes Stay
by Zacks Equity Research
On May 5, we issued an updated research report on Align Technology (ALGN), which manufactures a system of clear aligner therapy.
Qiagen Banks on Molecular Diagnostic amid Currency Woes
by Zacks Equity Research
On May 4, we issued an updated research report on leading molecular diagnostic company, Qiagen N.V. (QGEN).
CVS Down on Weak Earnings, Pharmacy Services Remains Strong
by Zacks Equity Research
On May 5, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS).
VWR Corp (VWR) Beats on Q1 Earnings, Awaits Merger Closure
by Zacks Equity Research
VWR Corporation (VWR) reported first-quarter 2017 adjusted earnings per share (EPS) of 44 cents, reflecting a 10% rise from the year-ago quarter.
Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) reported first-quarter 2017 loss of 14 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago figure of 35 cents.
BioScrip (BIOS) Q1 Loss Narrower than Expected, Sales Miss
by Zacks Equity Research
BioScrip, Inc. (BIOS) reported net loss from continuing operations of $19.4 million or a loss of 18 cents per share in the first quarter of 2017 compared with net loss of $9.5 million or a loss of 17 cents a year ago.